Natera
Progenity, Natera Jointly Request Dismissal of Patent Litigation
Progenity sought a declaratory judgment from a California court last year that its Innatal NIPT test didn't infringe six patents held by Natera.
Natera Q2 Revenues Grow 64 Percent
The company reported $142.0 million in total revenues for the quarter and said product revenues rose 71 percent from the prior-year quarter.
Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium
Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.
Natera Prices, Upsizes Public Stock Offering
The company said it plans to use the proceeds for working capital and general corporate purposes, and continued investments in R&D for its core technology.
Study investigators found that patients with ctDNA-positive results after surgery were at higher risk of bladder cancer recurrence than those who were ctDNA-negative.